Salesforce Q2 Earnings Top Estimates, Raise FY Guidance

Salesforce Q2 earnings beat consensus and raised FY27 revenue guidance, creating a near-term catalyst for traders focused on the stock's technicals.

August 26, 2026·2 min read
View all news articles
Flat vector cloud server sprouting compact agent modules to symbolize Salesforce Q2 earnings lift in AI ARR and margin gains

KEY TAKEAWAYS

  • Form 8-K showed Q2 revenue $11.3 billion and non-GAAP EPS $5.90, beating consensus.
  • Salesforce raised FY27 revenue guidance to $46.1-$46.4 billion and kept a 34.3% non-GAAP margin target.
  • Agentforce ARR reached $1.2 billion; company continued a $25.0 billion ASR and returned $364 million in dividends.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Salesforce (CRM) reported second-quarter fiscal 2027 earnings after the U.S. market close on Aug. 26, 2026, exceeding consensus expectations. The company raised its full-year revenue outlook, providing a near-term technical and fundamental catalyst for CRM stock.

Q2 Results and Financial Metrics

Salesforce disclosed results for the quarter ended July 31, 2026, in a Form 8-K filing. Revenue reached $11.3 billion, up 11.0% year over year. Subscription and support revenue rose 12.0% to $10.8 billion, including $440 million from Informatica.

GAAP diluted earnings per share (EPS) jumped 119.0% to $4.29, while non-GAAP diluted EPS increased 103.0% to $5.90. The company noted that non-GAAP results benefited from $2.6 billion in gains on strategic investments. GAAP operating margin was 20.5%, and non-GAAP operating margin was 34.1%.

Operating cash flow grew 71.0% to $1.3 billion, and free cash flow rose 81.0% to $1.1 billion. Salesforce returned $364 million in dividends and continued its $25 billion accelerated share-repurchase program.

Guidance and Market Context

Before the release, Salesforce guided Q2 revenue between $11.27 billion and $11.35 billion, with non-GAAP diluted EPS of $3.25 to $3.27 and GAAP diluted EPS of $1.74 to $1.76. Consensus estimates clustered near $11.32–$11.33 billion in revenue and $3.27 non-GAAP EPS, implying roughly 10–11% revenue growth and about 12% EPS growth compared with the prior-year quarter, which had revenue of $10.24 billion and non-GAAP EPS of $2.91.

The filing raised full-year fiscal 2027 revenue guidance to $46.1 billion–$46.4 billion and maintained a non-GAAP operating margin target of 34.3%.

Technical commentary ahead of the report described CRM stock as trading near its 200-day moving average after a more than 20% decline from prior highs, marking the quarter as a key catalyst. Management highlighted Agentforce, Salesforce’s AI platform, with annual recurring revenue (ARR) of $1.2 billion, up 205% year over year. Organic revenue growth excluding Informatica is expected to slow to about 6–7%, while new net annualized order value has outpaced existing-business growth for four consecutive quarters.

The stronger-than-expected quarter, upward revision to revenue guidance, and ongoing share repurchases reset near-term expectations for investors and traders following CRM stock.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Read other top news stories

Salesforce Revenue Forecast Rises on AI Momentum

Salesforce Revenue Forecast Rises on AI Momentum

Salesforce revenue forecast rose after a record quarter as AI agent adoption and an expanded Anthropic tie-up strengthened margins and prompted repositioning toward AI winners.

Williams-Sonoma Earnings Beat, Raises Outlook

Williams-Sonoma Earnings Beat, Raises Outlook

Williams-Sonoma earnings beat Q2 estimates as an IEEPA tariff refund lifted GAAP margins; the raised guidance supported near-term investor sentiment.

Photronics Q3 Results Show Margin Gain, Cautious Q4

Photronics Q3 Results Show Margin Gain, Cautious Q4

Photronics Q3 results beat guidance as high-end IC demand lifted margins; trimmed capex and a wide Q4 range signal near-term positioning risk for investors.

Nvidia Earnings Test AI Demand After PCE, GDP

Nvidia Earnings Test AI Demand After PCE, GDP

Nvidia earnings will test AI-driven revenue as July PCE stayed elevated and US GDP remained modest, potentially shifting near-term market flows.

Revolution Medicines FDA Approval Clears Rasonque

Revolution Medicines FDA Approval Clears Rasonque

Revolution Medicines FDA approval cleared RASONQUE for previously treated metastatic pancreatic cancer, boosting near-term investor positioning.

Boston Scientific Cyberattack Disrupts Shipments

Boston Scientific Cyberattack Disrupts Shipments

Boston Scientific cyberattack halted order processing and shipments, creating revenue and fulfillment risk as restoration timing remains unknown.